Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.		We did not use any antibodies.

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		We did not use any cell lines.
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		We did not use any cell lines.

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		We did not use any animals.
Animal observed in or captured from the field: Provide species, sex and age where possible		We did not use any animals.
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID		We did not use any model organisms.

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		We did not use any plants.
Microbes: provide species and strain, unique accession number if available, and source		We did not use any and icrobes

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		Our study did not involve human research participants
Provide statement confirming informed consent obtained from study participants.		Our study did not involve human
Report on age and sex for all study participants.		Our study did not involve human research

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.		It is not a clinical trial.

Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.		No additional step-by-step methodological details beyond what is provided in Methods section are available.

Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done**, or** if they were not carried out.		It is not a clinical trial.
Sample size determination		It is not a clinical trial.
Randomisation		It is not a clinical trial.
Blinding		It is not a clinical trial.
Inclusion/exclusion criteria		It is not a clinical trial.

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory		Our study does not contain these
Define whether data describe technical or biological replicates		Our study does not contain these

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		Our study does not contain these samples.
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		Our study does not contain these samples.
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		Our study does not contain these samples.

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		Study is not subject to consideration as dual use research

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		Our study does not contain these samples

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	"LinkedOmics analysis" section	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		We did not create new datasets
If data are publicly available, provide accession number in repository or DOI or URL.	"Methods" section	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		Publicly available data are not reused

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		There are no newly generated code and sousedftware
State whether the code or software is available.		There are no newly generated code and sousedftware
If code is publicly available, provide accession number in repository, or DOI or URL.		There are no newly generated code and sousedftware

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.	"Footnote" section	
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	"Introduction" section	

Article information: http://dx.doi.org/10.21037/ tcr-20-1045